Mabvax Therapeutics Holdings Inc. (MBVX) 2.1800 $MBVX
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
ACCESSWIRE - Wed Jul 01, 1:16PM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
OPK: 16.55 (-0.01)
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds
Marketwired - Wed Jul 01, 6:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"
, a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015.
OPK: 16.55 (-0.01)
MabVax's HuMab 5B1 Toxicology Results In Context
Mayer Winkler - at Seeking Alpha - Thu Jun 11, 9:52AM CDT
OPK: 16.55 (-0.01)
MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT
PR Newswire - Thu May 28, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.
MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015 Financial Results
Marketwired - Fri May 15, 7:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, provided today a corporate update and reported financial results for the first quarter ended March 31, 2015.
OPK: 16.55 (-0.01)
MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing
PR Newswire - Tue May 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent contract research organization. The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. These results further validate the Company's decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of 2015.
With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 28, 6:30AM CDT
OPK: 16.55 (-0.01), TEVA: 61.38 (-0.75)
The Real Value In MabVax May Be Partnerships Rather Than Pipeline
Mayer Winkler - at Seeking Alpha - Mon Apr 27, 9:47AM CDT
BLUE: 159.03 (+0.60), ZIOP: 11.17 (+0.69), BLCM: 19.58 (+0.74), OPK: 16.55 (-0.01), KITE: 64.36 (+1.05), CLLS: 35.72 (+1.27), JUNO: 52.05 (+1.72), ATRA: 54.17 (+0.76), NVS: 103.22 (+3.20), CELG: 118.84 (+1.97)
MabVax Therapeutics Analyst Brief by ARCE Research: Creating the Techniques to Fight Cancer in the Future Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Apr 17, 6:00AM CDT
MabVax Therapeutics Inc. (OTCQB: MBVX) based out of SAN DIEGO, CA is on the run to develop vaccines and antibodies based products to target specific forms of cancer. MabVax has an exclusive license to develop their vaccines at Memorial Sloan-Kettering Cancer Center (MSKCC). They then generate the monoclonal antibody with patients that have been treated with these licensed vaccines. MabVax is one of very few companies in the industry using this technique.
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 2.95 (+0.11), RTTR: 4.29 (-0.05), APRI: 1.76 (+0.01)
MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?
Greg Buch - at Seeking Alpha - Tue Apr 14, 6:52AM CDT
OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)
Opko Spots Another Overlooked Opportunity In MabVax Therapeutics
Wall Street Advisors - Seeking Alpha - Wed Apr 08, 10:13AM CDT
Opko Health (NYSE: OPK ) has a history of discerning overlooked assets in which to make strategic investments prior to value creation. Opko shareholders, in turn, get exposure to not only Opko's core assets, but also to a bevy of smaller, high growth...
OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)
MabVax Therapeutics Catches Eye of Billionaire Investor Dr. Phillip Frost and OPKO Health
Marketwired - Wed Apr 08, 7:30AM CDT
Investors at MabVax Therapeutics (OTCQB: MBVX) must feel like they're in just the right place at just the right time this week as news of billionaire Bio-Pharma Investor Dr. Phillip Frost, M.D., and his company OPKO Health (NYSE: OPK) have taken a strong interest in the clinical stage cancer immunotherapy company -- a $12 million interest. Dr. Frost is the CEO and Chairman of the Board at OPKO Health, and for those familiar with the good doctor, you already know that he and OPKO have a strong record of investing in biopharmaceutical firms.
OPK: 16.55 (-0.01)
MabVax Therapeutics elects Tom Varvaro to board
M2 - Wed Apr 08, 6:10AM CDT
Cancer immunotherapy company MabVax Therapeutics Holdings (OtherOTC:MBVX) reported on Tuesday that Tom Varvaro has been named as an independent director to its board of directors.
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 16.55 (-0.01), PFE: 34.36 (+0.50), JUNO: 52.05 (+1.72), NVCN: 6.59 (-0.02)
MabVax secures private financing of almost $12M; shares up 28%
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 10:04AM CDT
OPK: 16.55 (-0.01)
MabVax Therapeutics Announces Closing of Financing
PR Newswire - Mon Apr 06, 8:36AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company", a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement" led by OPKO Health, Inc. (NYSE: OPK) and Dr. Phillip Frost, CEO and Chairman of OPKO Health.
OPK: 16.55 (-0.01)
MabVax Receives Coverage with a $5 Near-Term Price Target Based on Upcoming Catalysts
ACCESSWIRE - Wed Jul 01, 1:16PM CDT
NEW YORK, NY / ACCESSWIRE / July 1, 2015 / Market Exclusive announces that today, John H. Ford, who primarily focuses on undervalued situations has initiated coverage in MabVax Therapeutics (OTCQB:MBVX).
OPK: 16.55 (-0.01)
MabVax Therapeutics Holdings Obtains Release of $3.5 Million in Escrowed Funds
Marketwired - Wed Jul 01, 6:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"
, a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015. OPK: 16.55 (-0.01)
MabVax's HuMab 5B1 Toxicology Results In Context
Mayer Winkler - at Seeking Alpha - Thu Jun 11, 9:52AM CDT
OPK: 16.55 (-0.01)
MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT
PR Newswire - Thu May 28, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.
MabVax Therapeutics Holdings, Inc. Provides Corporate Update and Reports First Quarter 2015 Financial Results
Marketwired - Fri May 15, 7:30AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, provided today a corporate update and reported financial results for the first quarter ended March 31, 2015.
OPK: 16.55 (-0.01)
MabVax Therapeutics' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing
PR Newswire - Tue May 05, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today it has received the final report on toxicology testing of its HuMab 5B1 antibody, which was completed by a leading independent contract research organization. The report detailed that the antibody, given in either a single dose or repeated doses, had no significant adverse findings even at the highest dosage levels tested. These results further validate the Company's decision to advance HuMab 5B1 into Phase 1 clinical trials before the end of 2015.
With 3 Near-Term Catalysts And Heavy Insider Buying, This Biotech Should Be In Your Portfolio Now
Lowenthal Capital Partners - at Seeking Alpha - Tue Apr 28, 6:30AM CDT
OPK: 16.55 (-0.01), TEVA: 61.38 (-0.75)
The Real Value In MabVax May Be Partnerships Rather Than Pipeline
Mayer Winkler - at Seeking Alpha - Mon Apr 27, 9:47AM CDT
BLUE: 159.03 (+0.60), ZIOP: 11.17 (+0.69), BLCM: 19.58 (+0.74), OPK: 16.55 (-0.01), KITE: 64.36 (+1.05), CLLS: 35.72 (+1.27), JUNO: 52.05 (+1.72), ATRA: 54.17 (+0.76), NVS: 103.22 (+3.20), CELG: 118.84 (+1.97)
MabVax Therapeutics Analyst Brief by ARCE Research: Creating the Techniques to Fight Cancer in the Future Issued by BrokerBank Securities, Inc.
PR Newswire - Fri Apr 17, 6:00AM CDT
MabVax Therapeutics Inc. (OTCQB: MBVX) based out of SAN DIEGO, CA is on the run to develop vaccines and antibodies based products to target specific forms of cancer. MabVax has an exclusive license to develop their vaccines at Memorial Sloan-Kettering Cancer Center (MSKCC). They then generate the monoclonal antibody with patients that have been treated with these licensed vaccines. MabVax is one of very few companies in the industry using this technique.
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
Business Wire - Tue Apr 14, 7:30AM CDT
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, announces the appointment of Paul V. Maier to the Company's Board of Directors. His addition increases Board membership to six directors. Mr. Maier will chair the Company's audit committee.
SQNM: 2.95 (+0.11), RTTR: 4.29 (-0.05), APRI: 1.76 (+0.01)
MabVax Therapeutics - A Bargain For Dr. Frost But Is It A Smart Buy For You?
Greg Buch - at Seeking Alpha - Tue Apr 14, 6:52AM CDT
OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)
Opko Spots Another Overlooked Opportunity In MabVax Therapeutics
Wall Street Advisors - Seeking Alpha - Wed Apr 08, 10:13AM CDT
Opko Health (NYSE: OPK ) has a history of discerning overlooked assets in which to make strategic investments prior to value creation. Opko shareholders, in turn, get exposure to not only Opko's core assets, but also to a bevy of smaller, high growth...
OPK: 16.55 (-0.01), JUNO: 52.05 (+1.72)
MabVax Therapeutics Catches Eye of Billionaire Investor Dr. Phillip Frost and OPKO Health
Marketwired - Wed Apr 08, 7:30AM CDT
Investors at MabVax Therapeutics (OTCQB: MBVX) must feel like they're in just the right place at just the right time this week as news of billionaire Bio-Pharma Investor Dr. Phillip Frost, M.D., and his company OPKO Health (NYSE: OPK) have taken a strong interest in the clinical stage cancer immunotherapy company -- a $12 million interest. Dr. Frost is the CEO and Chairman of the Board at OPKO Health, and for those familiar with the good doctor, you already know that he and OPKO have a strong record of investing in biopharmaceutical firms.
OPK: 16.55 (-0.01)
MabVax Therapeutics elects Tom Varvaro to board
M2 - Wed Apr 08, 6:10AM CDT
Cancer immunotherapy company MabVax Therapeutics Holdings (OtherOTC:MBVX) reported on Tuesday that Tom Varvaro has been named as an independent director to its board of directors.
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 16.55 (-0.01), PFE: 34.36 (+0.50), JUNO: 52.05 (+1.72), NVCN: 6.59 (-0.02)
MabVax secures private financing of almost $12M; shares up 28%
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 10:04AM CDT
OPK: 16.55 (-0.01)
MabVax Therapeutics Announces Closing of Financing
PR Newswire - Mon Apr 06, 8:36AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or "Company"
, a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement" led by OPKO Health, Inc. (NYSE: OPK) and Dr. Phillip Frost, CEO and Chairman of OPKO Health. OPK: 16.55 (-0.01)
